It is a multi-center, open-label clinical study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab. Entry criteria include ...
According to data released by GLOBOCAN 2020, lung cancer is currently the most prevalent malignant tumor with the highest mortality rate in China. Small ce...
Previously, there was no CAR-T cell therapy product in China for the treatment of adult large B-cell lymphoma who failed to respond to first-line immunoche...
“Samsung Biologics is fully committed to engaging in sustainable business practices for the positive impact it has on our clients, society, and the w...
"Blood cancers are a complex, heterogeneous set of diseases and while the treatment landscape has advanced in recent years, there is still a lot we don't k...
Join us for an in-depth conversation with Chua Keng Hock as we explore the challenges, strategies, and future prospects of the biopharma industry in today'...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases and ArriVent Bi...
Lenexa, Kansas, USA facility becomes company’s largest dry powder cell culture media facility and Center of Excellence in North America Boos...
Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies, a...
Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of technologically advanced healthcare products and services, ...
The clinical trial is a multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy profile of HMPL-415 ...
The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare coverage of LEQEMBI Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Nai...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has been informed it will receive national reimbursement ...
In phase I clinical trial, the single ascending doses (SAD) and multiple ascending doses (MAD) have been completed with ICP-488, demonstrating well-tolerat...
© 2025 Biopharma Boardroom. All Rights Reserved.
